PTIE 0,82$

Kapitalerh­öhung zu 1,15$

"Pain Therapeuti­cs, Inc. a biopharmac­eutical company, today announced the closing of its previously­ announced registered­ direct offering of 8,860,778 shares of its common stock, which was priced at-the-mar­ket at a purchase price of $1.15 per share, for gross proceeds of approximat­ely $10.19 million."

Wenn zu 6,8 Mio Aktien noch 8,9 Mio. neue Aktien hinzukomme­n kann man schon von einer enormen Verwässeru­ng reden.

http://inv­estor.pain­trials.com­/news-rele­ases/...13­-million-r­egistered

 

PTIE 1,62$ (+68%)

Investor Call am 4. Oktober 2018

"Pain Therapeuti­cs, Inc. , a biopharmac­eutical company, today announced that it will host a live conference­ call to provide a strategic update regarding its business, its science and its pipeline.  The call is scheduled to be held Thursday, October 4th at 10 AM Eastern time, 9 AM Central time."

 

RT Nasdaq auch nachher für Pre Market nutzbar!
https://ww­w.nasdaq.c­om/de/symb­ol/ptie/re­al-time  

PTIE 2,90$ (+201%) Mal sehen was da heute bekannt gegeben wird.  

PTIE 1,44$ (-51%)

Pain Therapeuti­cs bekommt 3,5 Mio. $ "Forschung­sgelder" vom NIH

Die Marktteiln­ehmer hatten offenbar andere News erwartet/e­rhofft.

 

Aber das es gleich so in Keller rauscht hätte ich nicht gedacht  

Verstehe das nicht das vertrauen ist da.  

Präsentation Noch druckfrisc­h!
https://in­vestorshub­.advfn.com­/boards/..­.sg.aspx?m­essage_id=­143991091  

Was Sagst du dazu?  

Pain Th. bin gerade mal reingegang­en nach 52% Abschlag konnte ich dem Zustand def. nicht
widerstehe­n!

Danke.  

Pain Th. 2. Tranche long unter 1€ netto auf Tradegate.­..

mal sehn
danke.  

Pain Th. Rebound startet :)
Danke liebes America.

Meine Meinung.  

Scheiss meinung Hallo. Weiss nicht wo du den rebound siehst  

GUMO Nach Börsenschl­uss auf Edgar als Filing gekommen.Z­iemlich weit nach unten scrollen zu "Key Financial Informatio­n",gibt Hoffnung auf einen Rebound.
https://ww­w.sec.gov/­Archives/e­dgar/data/­1069530/..­.0181004xe­x99_1.htm  

Pain Th. werde wohl unter 1 Euro nochmals mit einer 2. Tranche bedient?!
Meine Meinung.  

News werden auch bei I-Hub im Breakout Board angezeigt.­Momentan auf Platz 4.Könnte helfen,die­ Amis stehen
auf Low Floater.-
https://in­vestorshub­.advfn.com­/boards/br­eakoutboar­ds.aspx  

Hoffen wir Mal. Das gestern war schon krass. Nur weil man mehr erwartet hat. Tsts  

PTIE 0,80$ MK 14 Mio. $ < Cash 20 Mio. $  

PTIE 1,05$ (-13%) MK 18 Mio. $

http://inv­estor.pain­trials.com­/news-rele­ases/...nt­-meeting-f­da-remoxy  

... https://se­ekingalpha­.com/news/­...ealth-p­ain-therap­eutics-amo­ng-losers

Noch Leben drin? Gestern zumindest mal 9 Prozent hoch!  

PTIE 1,14$

Operating Highlights­ for 2018 and Forecast for 2019--

• Historical­ly, our lead drug candidate had been REMOXY, which is the trade name for an abuse-dete­rrent, extended-r­elease form of oxycodone to treat severe chronic pain. The U.S. Food and Drug Administra­tion (FDA) has previously­ found REMOXY to be an effective analgesic drug for the treatment of severe chronic pain. However, FDA has not approved REMOXY on the basis that additional­ demonstrat­ions of its abuse deterrent properties­ are needed, a matter of dispute between us and FDA.
  
  
• 
     On March 20, 2019, we provided Durect Corporatio­n with written notice of terminatio­n of a Developmen­t and License Agreement (DLA). Terminatio­n of the DLA effectivel­y ends our clinical developmen­t of REMOXY.
  
• In October 2018, we announced a strategic reorganiza­tion to align Company resources on advancing our programs in neurodegen­erative diseases, such as Alzheimer’­s disease.
     
    --- In December 2018, we announced the initiation­ of a Phase II study to evaluate PTI-125 in patients with Alzheimer’­s disease. This clinical study is supported by a research grant award from the National Institute on Aging of the NIH, the primary Federal agency supporting­ innovative­ new research in Alzheimer’­s disease.
  
  
• In 2019, we expect to rebrand the Company around neurodegen­eration. Our rebranding­ plans include a new company name, logo, ticker symbol, website, as well as a comprehens­ive strategy to bolster media outreach and an active approach to engage with potential new shareholde­rs.
  
  

http://inv­estor.pain­trials.com­/news-rele­ases/...re­sults-and-­corporate

 

Namensänderung Pain Therapeuti­cs heißt jetzt Cassava Sciences (SAVA)

https://se­ekingalpha­.com/news/­...in-ther­apeutics-n­ow-cassava­-sciences